PRE PRENETICS GLOBAL LIMITED

Nasdaq-Listed Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve

Nasdaq-Listed Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve

  • CircleDNA powers blockchain-based identity verification with Humanity Protocol, valued at US $1.1bn after latest fundraise
  • Prenetics invests $1.5M in Bitcoin, Solana and H tokens, supported by strong balance sheet
  • Prenetics advances Decentralized Science (DeSci) with AI-driven early cancer detection, backed by $30M investment from Tencent

CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading genomics and consumer healthcare company, today announced a groundbreaking genomics-based partnership with Humanity Protocol, a decentralized identity verification company. This collaboration leverages Prenetics’ advanced genetic testing capabilities to underpin decentralized identity verification.

Prenetics is bringing its flagship CircleDNA service into Humanity Protocol’s infrastructure as an Identity Validator. This integration enables the issuance of blockchain-based Proof of Personhood credentials, leveraging DNA testing to deliver highly secure and sybil-resistant identity verification. With advanced zero-knowledge proof technology, these credentials ensure robust privacy protection while supporting decentralized applications across finance, healthcare, and governance.

In coordination, and at the root of this partnership, Prenetics has formed a Crypto Strategic Reserve aimed at fueling innovation at the intersection of blockchain, healthcare, and decentralized science (DeSci). As part of the dual initiative, Prenetics is committing initial investments of $1 million in $H tokens, $250,000 in Bitcoin (BTC), and $250,000 in Solana (SOL). These allocations, which will be revisited on a quarterly basis to assess further investment opportunities, introduce the company’s digital asset investment strategy into its corporate balance sheet. Prenetics’ cash and short-term assets balance stood at $84.87 million as of December 31, 2024, reflecting its robust financial position to support these initiatives.

Danny Yeung, CEO and Co-Founder of Prenetics, stated: “Our partnership with Humanity Protocol exemplifies our commitment to merging the precision of genomics with the transformative potential of blockchain technology, particularly with the increasing validity of direct generative based advancements in healthcare. Through our CircleDNA service, we will provide secure, privacy-focused identity solutions that not only benefits decentralized applications across finance, healthcare, and governance but also paves the way for a strategic framework that permits Prenetics to integrate and capitalize on digital assets.”

Yat Siu, Board Director of the Humanity Foundation and Executive Chairman of Animoca Brands, added: “Prenetics’ entry into the decentralized identity arena as an Identity Validator marks a significant milestone. Their deep expertise in genomics, now combined with an active role in the Web3 ecosystem, is exactly the kind of forward-thinking collaboration that will drive decentralized identity and secure digital interactions into the future.”

On Prenetics’ Crypto Strategic Reserve, Mr. Yeung said: “Our Crypto Strategic Reserve demonstrates Prenetics’ confidence in the unfolding potential of blockchain and digital assets. This initiative not only diversifies our balance sheet and asset portfolio but also reinforces our commitment to a decentralized ecosystem by leveraging cutting-edge technologies to drive cross-industry innovation in healthcare and beyond.”

Advancing DeSci, AI-Driven Early Cancer Detection and Consumer Healthcare

Building on its blockchain and identity initiatives, Prenetics has historically been at the forefront of innovation in decentralized science (DeSci) through its joint venture company, Insighta. Currently advancing through clinical trials, Insighta is dedicated to making AI-driven early cancer detection accessible to millions worldwide. With its $30 million investment from Tencent, Insighta is leveraging Tencent’s advanced AI capabilities to accelerate groundbreaking discoveries in early cancer detection. Complementing this, Prenetics’ consumer health brand, IM8, is making a significant impact in the DeSci space by applying scientific advancements to promote daily health and longevity. Together, these efforts showcase how Prenetics is seamlessly integrating decentralized methodologies, precision genomics, cutting-edge artificial intelligence, and consumer healthcare to redefine innovation in global healthcare.

"Blockchain is creating unprecedented opportunities for innovation across industries," said Yeung. "By merging the rigor of genomics with digital innovation, we are forging a path toward a future where secure identity verification and groundbreaking healthcare solutions go hand in hand."

About Prenetics

Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a new health and wellness brand, and Europa, one of the largest sports distribution companies in the USA. Our clinical division is led by Insighta, our $200 million venture focused on multi-cancer early detection technologies. Each of Prenetics’ units synergistically enhances our global impact on health, embodying our commitment to ‘enhancing life through science’. To learn more about Prenetics, please visit prenetics.com.

About Humanity Protocol

Humanity Protocol is an innovative decentralized identity solution that employs advanced technologies—ranging from palm recognition to DNA-based testing—to establish robust Proof of Humanity credentials. Its privacy-centric approach ensures sybil-resistant identity verification across various Web3 applications.

About Animoca Brands

Animoca Brands is a global leader in gamification, blockchain, and digital property rights. With a diverse portfolio of over 380 investments in Web3 projects, the company is dedicated to fostering innovation in the metaverse and driving the adoption of blockchain technologies across multiple industries.

Investor Relations Contact:



Angela Cheung

Investor Relations / Corporate Finance

Prenetics Global Limited



EN
11/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PRENETICS GLOBAL LIMITED

 PRESS RELEASE

Prenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing C...

Prenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) --  , the premium supplements brand co-founded by David Beckham, today announced the addition of two distinguished new members, Dr. Jeremy London and Dr. Amy Shah, to its world-class (SAB). These additions underscore IM8’s unwavering commitment to leading innovation in science, lo...

 PRESS RELEASE

Prenetics to Participate in the 37th Annual ROTH Conference

Prenetics to Participate in the 37th Annual ROTH Conference CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA. Prenetics’ Chief Executive Officer Danny Yeung and President of Americas David Vanderveen will be available to host one-on-one meetings with investors during the event. In addition, management will participate...

 PRESS RELEASE

Prenetics Announces Fourth Quarter and Full Year 2024 Financial Result...

Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance Revenue grew 93.5% to $10.5 million in the fourth quarter and 40.9% year-over-year to $30.6 million in 2024 Cash and short-term assets of $84.8 million as of December 31, 2024 Provides first quarter and full year 2025 guidance Projects full year 2025 revenue of $73 million to $85 million, driven by the strong launch of CHARLOTTE, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences ...

 PRESS RELEASE

Nasdaq-Listed Prenetics Announces Genomics-Based Partnership with Huma...

Nasdaq-Listed Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve CircleDNA powers blockchain-based identity verification with Humanity Protocol, valued at US $1.1bn after latest fundraisePrenetics invests $1.5M in Bitcoin, Solana and H tokens, supported by strong balance sheetPrenetics advances Decentralized Science (DeSci) with AI-driven early cancer detection, backed by $30M investment from Tencent CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading genomics and consumer healthcare...

 PRESS RELEASE

Prenetics Unveils IM8 to U.S. Consumers with Co-Founding Partner David...

Prenetics Unveils IM8 to U.S. Consumers with Co-Founding Partner David Beckham The Next Big Thing in Wellness? IM8 Lands in the U.S. with a Star-Studded Launch. David Beckham and a world-class scientific team are putting the focus back on foundational health CHARLOTTE, N.C., Jan. 21, 2025 (GLOBE NEWSWIRE) -- , a premium supplements brand co-founded by David Beckham, hosted its U.S. unveiling event in New York City on January 14. The two-part event featured an Inside Out Wellness session with holistic health advocate Deepak Chopra, M.D., and David Beckham, followed by An Evening with IM8 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch